Stockreport

Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Harpoon Therapeutics, Inc.  (HARP) 
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm Check Earnings Report
PDF The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts.Safety data continu [Read more]